Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Registration Number
- NCT03240315
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Brief Summary
This is a 3 year longitudinal study to establish a personalized prediction and prevention system for acute exacerbation of chronic obstructive pulmonary disease（AECOPD). Data will be collected which contained with clinical, pathophysiology, etiology and immunology information of chronic obstructive pulmonary disease(COPD) patients and analyzed by data mining combined with Internet technology.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 400
-
Patients was diagnosed as COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines older than 40 years old.
- A signed and dated written informed consent is obtained prior to participation.
- Able to comply with the requirements of the protocol and be available for study visits over 3 years.
-
A COPD subject will not be eligible for inclusion in this study if any of the following criteria apply:
- Known respiratory disorders, or disorders identified at screening/visit 1 (including identification on the first CT scan), other than COPD (e.g.: lung cancer, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis)
- Known history of significant inflammatory disease, other than COPD (e.g. rheumatoid arthritis and Lupus)
- Known to be severely alpha-1-antitrypsin deficient
- Has experienced a moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) within the last 4 weeks
- Having undergone lung surgery (e.g. lung reduction, lung transplant)
- Have cancer or have had cancer in the 5 years prior to study entry
- Having received a blood transfusion in the 4 weeks prior to study start
- Inability to walk
- Taking part in a blinded drug study
- Having therapy with systemic corticosteroids at inclusion.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Establishment of prediction platform for COPD exacerbation 3 years The patients with chronic obstruction pulmonary disease will be followed up at intervals of 3 months for 3 years by the Modified British Medical Research Council (mMRC) score scale,spirometric analysis, sputum smear,questionnaire and so on. An exacerbation of COPD was diagnosed according to GOLD guidelines. Time to the first acute exacerbation and average number of acute exacerbations per year in COPD subjects will be record.Research of AECOPD Risk factors based on complex network analysis.Identification and validation of COPD exacerbations risk stratification and predictive markers based on data mining.
- Secondary Outcome Measures
Name Time Method Pathogenic microorganism and drug resistance monitoring for COPD exacerbation 3 years Dynamics of pathogenic microorganism and drug resistance in natural course of COPD will be investigated by using the metagenome technique and the culture technique.
Developing new protein chips for AECOPD 3 years Systemic and airway autoantibody profiles and cytokine profiles will be measured using commercial multiplex bead-based assay to screen out a set of ideal AECOPD-related markers.
Detection of immune repertoire in COPD/AECOPD 3 years Immune status of COPD patients will be investigated by using the immune repertoire technique and its relationship with the pathophysiology of AECOPD will be identified.
Trial Locations
- Locations (1)
Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China